The first report of this function in cancer cells was published by Cuellar TL et al. in 2017 when the authors demonstrated that SETDB1 silencing, by decreasing H3K9me3 at repetitive loci in AML cells, elevates the expression of IFN-β and interferon-stimulated genes [51]. This evidence concerns the gene SETDB1 and cancer.